Ketamine Troches for Chronic Pain

A ketamine troche for chronic pain works by blocking NMDA receptors involved in central sensitization, the process that causes the nervous system to amplify pain signals beyond what an injury alone would explain. Ketamine was developed and approved as an anesthetic, and its analgesic effects are part of its core pharmacology, not a side benefit discovered later. For people with neuropathic pain, complex regional pain syndrome (CRPS), fibromyalgia, or pain that has stopped responding to opioids, sublingual ketamine troches offer a home-based option that can fit into a broader pain management plan.

How Ketamine Works for Chronic Pain

NMDA Receptor Blockade and Wind-Up

Chronic pain often involves central sensitization, a state in which the nervous system becomes hypersensitive to pain signals and keeps amplifying them beyond what the original injury would predict. This process is driven largely by NMDA receptors, a type of glutamate receptor found in the spinal cord's dorsal horn (see PubChem's ketamine compound summary for the underlying chemical and pharmacological data). Repeated or intense pain input activates these receptors in a process called wind-up, where each subsequent pain signal produces a larger neuronal response than the one before it.

Ketamine blocks NMDA receptors, which interrupts wind-up and reduces central sensitization. According to StatPearls, NMDA receptor antagonism is central to both ketamine's anesthetic and analgesic effects. This helps explain why pain relief from ketamine can outlast the drug's presence in the bloodstream, since the neuroplastic changes it triggers in pain processing circuits may persist for days to weeks after the drug has cleared.

Opioid Receptor Interaction

Ketamine also binds to opioid receptors, particularly sigma and mu receptors, as part of its analgesic action. It can reverse opioid-induced hyperalgesia, the paradoxical increase in pain sensitivity that develops with long-term opioid use. For patients on chronic opioid therapy who have developed tolerance or hyperalgesia, ketamine may help restore opioid efficacy and support dose reduction.

Anti-Inflammatory Effects

Ketamine has shown anti-inflammatory effects at the cellular level, reducing production of pro-inflammatory cytokines that contribute to pain sensitization in conditions such as CRPS and fibromyalgia.

Conditions Most Likely to Respond

Complex Regional Pain Syndrome (CRPS)

CRPS is a chronic, severe pain condition that typically develops in a limb after an injury and involves burning pain, allodynia, and autonomic changes, with central sensitization as a core feature. Ketamine has the strongest evidence base for CRPS among chronic pain conditions, with multiple open-label studies and some controlled trials showing significant pain reduction, particularly with high-dose IV protocols. Troche-based protocols typically use lower doses than IV infusion but can provide meaningful supplemental relief and functional improvement as part of a multimodal plan. See our comparison of troche and infusion outcomes for how the two delivery methods differ.

Fibromyalgia

Fibromyalgia involves widespread musculoskeletal pain, fatigue, and tenderness without identifiable tissue damage, and central sensitization is the dominant mechanism. Ketamine's effect on central pain processing makes it a rational treatment option, and several studies have found pain reduction and improved function in fibromyalgia patients receiving ketamine. Troche doses for fibromyalgia typically fall in the low to moderate range, around 50 to 200 mg, aiming to modulate central pain without producing the more pronounced dissociative effects used in psychiatric protocols.

Neuropathic Pain

Neuropathic pain arises from damage or dysfunction of the nervous system rather than tissue injury, and it responds poorly to traditional analgesics but often responds to NMDA receptor antagonists. Ketamine troches have been used for diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury pain, and phantom limb pain. Clinical outcomes are generally positive, though most evidence comes from case series and small trials rather than large controlled studies.

Opioid-Refractory Pain

Patients whose chronic pain remains inadequately controlled despite opioid therapy, whether from tolerance or opioid-induced hyperalgesia, may benefit from ketamine's ability to reset central sensitization and potentially restore opioid responsiveness.

Migraine

Ketamine has been used in inpatient settings for refractory migraines with some reported success. Troche-based use for migraine prevention or acute treatment is less established but has been reported clinically.

Dosing for Chronic Pain: How It Differs from Psychiatric Protocols

Chronic pain dosing with troches typically looks different from mental health protocols. Pain management often uses sub-anesthetic, sub-dissociative doses that produce analgesic effects without a pronounced psychoactive experience. Typical pain management troche doses range from 50 to 150 mg, compared to the 150 to 400 mg range common in depression protocols. Our guide to troche onset, peak, and duration covers how quickly these doses take effect.

At these lower doses, patients typically remain fully functional, experience minimal to no dissociative effects, and can use the troche more frequently, in some protocols daily, with less risk of significant adverse effects.

Frequency for pain management can also differ from psychiatric use. Some providers use low-dose troches, around 50 to 100 mg, daily or most days of the week as analgesic maintenance. Others follow a twice-weekly schedule similar to psychiatric maintenance protocols, or reserve troches for as-needed use during pain flares. The right frequency depends on the pain condition, how it naturally fluctuates, and how the patient responds.

It helps to distinguish sub-dissociative analgesic dosing, low doses around 50 to 100 mg that relieve pain without significant altered states and suit daytime use, from full psychedelic or dissociative dosing, doses of 200 mg or more that produce a full altered-state experience and are typically reserved for psychiatric indications or cases where the therapeutic experience itself supports pain management. Some patients benefit from periodic full-dose sessions, which can address both pain and the psychological burden of chronic illness, combined with more frequent sub-dissociative doses for daily pain control.

Pain and Psychological Comorbidity

Chronic pain and psychiatric conditions are closely linked. According to the World Health Organization, depression affects a significant share of adults worldwide and commonly co-occurs with chronic physical health conditions. In chronic pain populations specifically, depression is estimated to affect roughly 30 to 50 percent of patients, with anxiety similarly common. Pain catastrophizing, a cognitive pattern involving excessive focus on pain, feelings of helplessness, and rumination, can amplify the pain experience and increase disability.

Ketamine's antidepressant and anxiolytic effects, combined with its direct analgesic mechanism, make it well suited to the common clinical picture of chronic pain with comorbid depression or anxiety. Treating both at once, rather than managing pain and mood separately, is a meaningful advantage. For more on how ketamine is used for mood symptoms alongside pain, see our guide to treatment-resistant depression and troche options.

Limitations and Cautions

Ketamine troches are not appropriate as the sole treatment for chronic pain. They work best as part of a multimodal pain management approach that may include physical therapy, other pharmacological agents such as anticonvulsants, SNRIs, or topical treatments as appropriate, psychological pain management such as CBT for chronic pain or acceptance and commitment therapy, and interventional procedures when indicated.

The goal of ketamine in a pain protocol is to reset central sensitization and open a window for functional rehabilitation, not to provide indefinite analgesic coverage in place of comprehensive care. Review your full treatment plan and any side effects with your provider; our troche safety guide and guide to working with your provider cover what to discuss before and during treatment.